Conditions: Hepatitis C
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 4
Healthy volunteers: no

Brief summary:
The goal of this study was to compare hepatic pharmacokinetics (PK) derived from liver tissue to plasma PK after administration of grazoprevir (MK-5172) to participants with chronic hepatitis C virus (HCV) infection. Participants will be randomized to one of four different liver ultrasound-guided Fine Needle Aspirate (FNA) schedules (at 4-, 8-, 24-, or 72-hours after the Day 7 dose).

Detailed description:

Arms:
arm 1: Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.

Interventions: intervention 1: Grazoprevir
Intervention descriptions: intervention 1: GZR 100 mg tablet by mouth q.d. for 7 days.

Protocol document: